{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:25:47Z","timestamp":1783635947108,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Qingdao Key Medical and Health Discipline Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46378-0","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:47:27Z","timestamp":1774846047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The association of TyG-BMI with MAFLD and liver fibrosis: a cross-sectional study"],"prefix":"10.1038","volume":"16","author":[{"given":"Xiaoyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"3","key":"46378_CR1","first-page":"619","volume":"21","author":"GEH Lim","year":"2023","unstructured":"Lim, G. E. H. et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD [J]. Clinical gastroenterology and hepatology: the official clinical practice. J. Am. Gastroenterological Association. 21 (3), 619\u2013629e617 (2023).","journal-title":"J. Am. Gastroenterological Association"},{"issue":"8","key":"46378_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao, L. et al. Current status and future trends of the global burden of MASLD [J]. Trends Endocrinol. Metab. 35 (8), 697\u2013707 (2024).","journal-title":"Trends Endocrinol. Metab."},{"issue":"3","key":"46378_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"YOUNOSSI Z M","year":"2019","unstructured":"YOUNOSSI Z M. Non-alcoholic fatty liver disease - A global public health perspective [J]. J. Hepatol. 70 (3), 531\u2013544 (2019).","journal-title":"J. Hepatol."},{"issue":"4","key":"46378_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang, D. Q., El-serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention [J]. Nat. reviews Gastroenterol. Hepatol. 18 (4), 223\u2013238 (2021).","journal-title":"Nat. reviews Gastroenterol. Hepatol."},{"issue":"10290","key":"46378_CR5","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease [J]. Lancet (London England). 397 (10290), 2212\u20132224 (2021).","journal-title":"Lancet (London England)"},{"issue":"2","key":"46378_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","volume":"70","author":"RS Khan","year":"2019","unstructured":"Khan, R. S. et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease [J]. Hepatol. (Baltimore Md). 70 (2), 711\u2013724 (2019).","journal-title":"Hepatol. (Baltimore Md)"},{"key":"46378_CR7","doi-asserted-by":"publisher","first-page":"104984","DOI":"10.1016\/j.phrs.2020.104984","volume":"159","author":"CH Zhang","year":"2020","unstructured":"Zhang, C. H. et al. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies [J]. Pharmacol. Res. 159, 104984 (2020).","journal-title":"Pharmacol. Res."},{"issue":"21","key":"46378_CR8","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jacc.2007.01.088","volume":"49","author":"J Jeppesen","year":"2007","unstructured":"Jeppesen, J. et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study [J]. J. Am. Coll. Cardiol. 49 (21), 2112\u20132119 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"46378_CR9","first-page":"E214","volume":"237","author":"RA Defronzo","year":"1979","unstructured":"Defronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: a method for quantifying insulin secretion and resistance [J]. Am. J. Physiol. 237 (3), E214\u2013223 (1979).","journal-title":"Am. J. Physiol."},{"key":"46378_CR10","doi-asserted-by":"crossref","unstructured":"s\u00e1nchez-garc\u00eda, A. et al. Diagnostic Accuracy of the Triglyceride and Glucose Index for Insulin Resistance: A Systematic Review [J]. International journal of endocrinology, 2020: 4678526. (2020).","DOI":"10.1155\/2020\/4678526"},{"issue":"8","key":"46378_CR11","doi-asserted-by":"publisher","first-page":"102581","DOI":"10.1016\/j.dsx.2022.102581","volume":"16","author":"DL Tahapary","year":"2022","unstructured":"Tahapary, D. L. et al. Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride\/glucose index [J]. Diabetes metabolic syndrome. 16 (8), 102581 (2022).","journal-title":"Diabetes metabolic syndrome"},{"issue":"3","key":"46378_CR12","doi-asserted-by":"publisher","first-page":"e0149731","DOI":"10.1371\/journal.pone.0149731","volume":"11","author":"LK Er","year":"2016","unstructured":"Er, L. K. et al. Triglyceride Glucose-Body Mass Index Is a Simple and Clinically Useful Surrogate Marker for Insulin Resistance in Nondiabetic Individuals [J]. PloS one. 11 (3), e0149731 (2016).","journal-title":"PloS one"},{"key":"46378_CR13","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/DMSO.S409983","volume":"16","author":"H Li","year":"2023","unstructured":"Li, H. et al. Relationship Between Six Insulin Resistance Surrogates and Nonalcoholic Fatty Liver Disease Among Older Adults: A Cross-Sectional Study [J]. Diabetes metabolic syndrome obesity: targets therapy. 16, 1685\u20131696 (2023).","journal-title":"Diabetes metabolic syndrome obesity: targets therapy"},{"issue":"22","key":"46378_CR14","doi-asserted-by":"publisher","first-page":"e7041","DOI":"10.1097\/MD.0000000000007041","volume":"96","author":"S Zhang","year":"2017","unstructured":"Zhang, S. et al. Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects [J]. Medicine 96 (22), e7041 (2017).","journal-title":"Medicine"},{"issue":"1","key":"46378_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12967-022-03611-4","volume":"20","author":"H Hu","year":"2022","unstructured":"Hu, H. et al. The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population [J]. J. translational Med. 20 (1), 398 (2022).","journal-title":"J. translational Med."},{"issue":"1","key":"46378_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12944-021-01561-2","volume":"20","author":"G Sheng","year":"2021","unstructured":"Sheng, G. et al. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease [J]. Lipids Health Dis. 20 (1), 134 (2021).","journal-title":"Lipids Health Dis."},{"key":"46378_CR17","doi-asserted-by":"publisher","first-page":"1308265","DOI":"10.3389\/fendo.2023.1308265","volume":"14","author":"AH Kim","year":"2023","unstructured":"Kim, A. H. Son d h, Lee y j. Modified triglyceride-glucose index indices are reliable markers for predicting risk of metabolic dysfunction-associated fatty liver disease: a cross-sectional study [j]. Front. Endocrinol. 14, 1308265 (2023).","journal-title":"Front. Endocrinol."},{"issue":"8","key":"46378_CR18","doi-asserted-by":"publisher","first-page":"e0324483","DOI":"10.1371\/journal.pone.0324483","volume":"20","author":"YG Boushehri","year":"2025","unstructured":"Boushehri, Y. G. et al. Association of triglyceride glucose-body mass index (tyg-bmi) with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis [j]. Plos one. 20 (8), e0324483 (2025).","journal-title":"Plos one"},{"key":"46378_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni, G. et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population [j]. BMC Gastroenterol. 6, 33 (2006).","journal-title":"BMC Gastroenterol."},{"issue":"5","key":"46378_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (cap) technology for assessing steatosis [j]. J. Hepatol. 66 (5), 1022\u20131030 (2017).","journal-title":"J. Hepatol."},{"issue":"1","key":"46378_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement [j]. J. Hepatol. 73 (1), 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"issue":"1","key":"46378_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12944-021-01506-9","volume":"20","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Usefulness of the triglyceride glucose-body mass index in evaluating nonalcoholic fatty liver disease: insights from a general population [j]. Lipids Health Dis. 20 (1), 77 (2021).","journal-title":"Lipids Health Dis."},{"issue":"1","key":"46378_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12944-020-01409-1","volume":"19","author":"Li","year":"2020","unstructured":"Li et al. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study [j]. Lipids Health Dis. 19 (1), 229 (2020).","journal-title":"Lipids Health Dis."},{"key":"46378_CR24","doi-asserted-by":"crossref","unstructured":"Zeng, Z. Y. et al. Association of triglyceride glucose index and its combination of obesity indices with prehypertension in lean individuals: a cross-sectional study of chinese adults [j]. Journal of clinical hypertension (greenwich). 22(6), 1025\u20131032 (2020).","DOI":"10.1111\/jch.13878"},{"issue":"4","key":"46378_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ajg.2011.400","volume":"107","author":"DH Sinn","year":"2012","unstructured":"Sinn, D. H. & park Gwak, G. Y. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged asian adults [j]. Am. J. Gastroenterol. 107 (4), 561\u2013567 (2012).","journal-title":"Am. J. Gastroenterol."},{"issue":"8","key":"46378_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cgh.2012.03.011","volume":"10","author":"DM Torres","year":"2012","unstructured":"Torres, D. M., Williams, C. D. & Harrison, S. A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease [j]. Clin. Gastroenterol. hepatology: official Clin. Pract. J. Am. gastroenterological association. 10 (8), 837\u2013858 (2012).","journal-title":"Clin. Gastroenterol. hepatology: official Clin. Pract. J. Am. gastroenterological association"},{"key":"46378_CR27","doi-asserted-by":"publisher","first-page":"8096","DOI":"10.1038\/srep08096","volume":"5","author":"W Jiang","year":"2015","unstructured":"Jiang, W. et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease [j]. Sci. Rep. 5, 8096 (2015).","journal-title":"Sci. Rep."},{"key":"46378_CR28","doi-asserted-by":"crossref","unstructured":"Liu, C. H. et al. Sarcopenia and masld: novel insights and the future [j] (Nature reviews endocrinology, 2025).","DOI":"10.1038\/s41574-025-01197-7"},{"issue":"2","key":"46378_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000536447","volume":"17","author":"Han","year":"2024","unstructured":"Han & Zhang, K. Triglycerides mediate the influence of body mass index on non-alcoholic fatty liver disease in a non-obese chinese population with normal low-density lipoprotein cholesterol levels [j]. Obes. Facts. 17 (2), 191\u2013200 (2024).","journal-title":"Obes. Facts"},{"issue":"1","key":"46378_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","volume":"7","author":"M Li","year":"2022","unstructured":"Li, M. et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy [j]. Signal. Transduct. Target. therapy. 7 (1), 216 (2022).","journal-title":"Signal. Transduct. Target. therapy"},{"issue":"7","key":"46378_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","volume":"63","author":"F Ameer","year":"2014","unstructured":"Ameer, F. et al. De novo lipogenesis in health and disease [j]. Metab. Clin. Exp. 63 (7), 895\u2013902 (2014).","journal-title":"Metab. Clin. Exp."},{"issue":"1","key":"46378_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12876-025-04087-4","volume":"25","author":"X Huang","year":"2025","unstructured":"Huang, X. et al. Tyg-bmi as a superior predictor of mafld and pre-mafld in chinese adults: a cross-sectional study [j]. BMC Gastroenterol. 25 (1), 495 (2025).","journal-title":"BMC Gastroenterol."},{"issue":"8","key":"46378_CR33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamainternmed.2025.1809","volume":"185","author":"P Ochoa-allemant","year":"2025","unstructured":"Ochoa-allemant, P. et al. Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease [j]. Jama Intern. Med. 185 (8), 986\u2013995 (2025).","journal-title":"Jama Intern. Med."},{"key":"46378_CR34","doi-asserted-by":"crossref","unstructured":"Ekstedt, M., Hagstr\u00f6m, H. & nasr p, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in nafld after up to 33 years of follow-up [j]. Hepatology.  61(5), 1547\u20131554 (2015).","DOI":"10.1002\/hep.27368"},{"issue":"3","key":"46378_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva, T. & Brenner, D. Molecular and cellular mechanisms of liver fibrosis and its regression [J]. Nat. reviews Gastroenterol. Hepatol. 18 (3), 151\u2013166 (2021).","journal-title":"Nat. reviews Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46378-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:46:41Z","timestamp":1774950401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46378-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46378"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46378-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Ethics Review Committee of the Qingdao Sixth People\u2019s Hospital (No.2025030602). The patients\/participants provided written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"10590"}}